Safety First

Patient Safety First

Ibogaine is powerful medicine that has helped hundreds of patients when administered safely. It has also caused fatalities when administered without proper screening. We are transparent about both.

Critical safety notice: Ibogaine prolongs the cardiac QT interval and can cause fatal arrhythmias in patients with undetected cardiac abnormalities. Every fatality reported at ibogaine facilities has involved either an undetected cardiac condition, a dangerous medication interaction, or inadequate medical monitoring. Our screening protocols exist to prevent these outcomes. We will decline to treat patients who do not complete full screening, including those who misrepresent their medical history.
Absolute Contraindications

Conditions That Preclude Treatment

The following conditions represent absolute contraindications. Patients with these conditions will not be accepted for treatment, regardless of how compelling their clinical case may otherwise be.

Cardiac Contraindications

  • Long QT syndrome (congenital or acquired, QTc >450ms)
  • Brugada syndrome (Pattern 1 ECG findings)
  • Wolff-Parkinson-White (WPW) syndrome
  • Recent myocardial infarction (within 6 months)
  • Congestive heart failure (NYHA Class III to IV)
  • Second- or third-degree heart block
  • History of sudden cardiac arrest or ventricular fibrillation
  • Uncontrolled atrial fibrillation

Other Absolute Contraindications

  • Hepatic failure or severe hepatic impairment (Child-Pugh C)
  • Pregnancy or breastfeeding
  • Cerebellar ataxia or significant cerebellar disease
  • Active psychosis (schizophrenia, schizoaffective disorder, acute manic episode)
  • Severe respiratory failure
  • Active suicidal ideation with intent and plan
Medication Interactions

Medication Contraindications & Requirements

Many medications can be safely managed with the right protocol, but this requires honest, complete disclosure. Withholding medication information is the single greatest risk factor we encounter.

SSRIs & SNRIs

Must be tapered and discontinued for a minimum of 2 weeks before treatment (4 to 6 weeks preferred for fluoxetine due to long half-life). Risk: serotonin syndrome. Taper must be physician-supervised.

critical
Methadone

Requires a specific bridging protocol, transition to a short-acting opioid (typically morphine or oxycodone) for 7 to 14 days before treatment. Standard ibogaine protocols are not safe with active methadone on board. We manage this process with you.

critical
Benzodiazepines

Low doses taken as prescribed may be managed with guidance. High-dose or long-term benzodiazepine use requires a physician-supervised taper prior to treatment. Ibogaine does not address benzo dependence. we are honest about this.

high
Antiarrhythmic Drugs

Class I and III antiarrhythmics (amiodarone, sotalol, flecainide, quinidine) are absolute contraindications due to additive QT prolongation risk. Require thorough cardiac evaluation and cardiologist consultation.

critical
QTc-Prolonging Antibiotics

Fluoroquinolones (ciprofloxacin, levofloxacin), azithromycin, and clarithromycin prolong QTc and must be completed and cleared before treatment. Minimum 5 half-lives clearance required.

high
Lithium

Must be discontinued with physician guidance prior to treatment due to neurotoxicity risk and QT effects. Requires careful tapering and monitoring.

critical
MAO Inhibitors

Strict contraindication. MAOIs must be completely cleared (minimum 14 days for irreversible MAOIs) before any ibogaine administration. Risk of hypertensive crisis and serotonin syndrome.

critical
Tramadol

Lowers seizure threshold significantly. Must be discontinued and cleared prior to treatment. Tramadol withdrawal also requires careful management, discuss with our team.

high
Relative Contraindications

Conditions Requiring Case-by-Case Review

Relative contraindications do not automatically exclude a patient from treatment. they require individualized evaluation, additional testing, and possibly protocol modifications.

Age >65 (individualized cardiac evaluation required, not an automatic exclusion)
BMI >40 (dosing complexity and respiratory monitoring considerations)
Controlled seizure disorder with stable antiepileptic regimen (case-by-case assessment)
Moderate hepatic impairment (Child-Pugh B), dose reduction and extended monitoring
Moderate renal impairment, pharmacokinetic considerations
Poorly controlled hypertension (requires pre-treatment stabilization)
Type 1 diabetes (glycemic monitoring intensive)
History of cardiac arrhythmia currently well-managed
Pre-Treatment Testing

Required Pre-Treatment Evaluations

12-Lead ECG

Required

The single most critical pre-screening test. Must be interpreted by a physician reviewing QT interval, QRS morphology, and Brugada pattern. Required within 30 days of treatment.

Comprehensive Metabolic Panel (CMP)

Required

Evaluates kidney function (BUN, creatinine), liver enzymes (ALT, AST, ALP), electrolytes (critical for QT assessment), and glucose. Must be within 30 days of treatment.

Liver Function Panel

Required

Total bilirubin, direct bilirubin, albumin, PT/INR. Assesses hepatic capacity to metabolize ibogaine (primarily CYP2D6). Critical for safe dosing.

Complete Blood Count (CBC)

Required

Evaluates baseline hematologic status. Anemia, thrombocytopenia, or leukopenia may require evaluation prior to treatment.

Urine Drug Screen (UDS)

Required

10-panel minimum. Required to confirm accuracy of reported substance use and identify any undisclosed substances that could create dangerous interactions.

Pregnancy Test

Required

Required for all patients who could be pregnant. Ibogaine is absolutely contraindicated in pregnancy.

CYP2D6 Genotyping

Recommended

Ibogaine is primarily metabolized by CYP2D6. Poor metabolizers (~7% of population) face significantly higher plasma levels and require dose adjustment. Strongly recommended.

Echocardiogram

Recommended

Required for patients with any cardiac history, ECG abnormalities, or significant cardiovascular risk factors. Evaluates structural heart disease and ejection fraction.

Our Protocols

How We Keep You Safe During Treatment

01

Continuous Cardiac Monitoring

Telemetry-grade ECG monitoring throughout the active treatment window and recovery period. QTc is tracked continuously. Any QTc prolongation >500ms triggers immediate clinical protocol.

02

Vital Signs q30min

Blood pressure, pulse, oxygen saturation, and temperature are recorded every 30 minutes throughout the acute experience. More frequent if any parameter is outside normal range.

03

Emergency Medications On-Site

IV magnesium sulfate (for QT management), lidocaine, epinephrine, atropine, defibrillator, and full ACLS medication kit are immediately accessible throughout every treatment.

04

Board-Certified Physicians

Our medical director and supervising physicians hold board certifications in emergency medicine, internal medicine, and/or anesthesiology. Not nurses. Physicians.

05

Hospital Transfer Protocol

A signed hospital transfer agreement with a cardiac-capable hospital within 20 minutes of our facility. If transfer is needed, it happens immediately, not after deliberation.

06

No Overbooking Policy

We treat one patient at a time per physician. Medical oversight is never diluted by treating multiple patients simultaneously with complex protocols.

Honest Assessment

Who Should Not Do Ibogaine

We turn away patients when it is the right thing to do. This is not a commercial consideration. it is a medical one.

  • Anyone with a confirmed cardiac conduction abnormality who has not completed full cardiac workup
  • Anyone currently taking methadone who has not completed our bridging protocol
  • Anyone with active, untreated psychosis
  • Anyone who is pregnant or may be pregnant
  • Anyone in hepatic failure
  • Anyone who is unwilling to disclose their complete medication list
  • Anyone seeking ibogaine as a single magic solution without commitment to integration
  • Anyone whose medical team has clearly contraindicated the treatment after full review
Start With Screening

Find Out If You Are a Candidate

Our prescreen takes 15 minutes and gives you and our medical team the information needed to make an honest assessment. If you are not a candidate, we will tell you, and help you understand what your options are.

Get Screened